RxDoctor Payments Data

Binh Nguyen, DO

Cardiovascular Disease · Pontiac, MINPI 1093933665

Payments from drug & device makers

$1,044in general payments, 2019–2025

Across 22 payments — averaging $47.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$580
  • Amgen$164
  • Abbott$79
  • Johnson & Johnson$43
  • Medtronic$42
  • Sunovion Pharmaceuticals Inc.$40
  • plus $97 from 5 others

What the payments were for

  • Travel & lodging$44342%
  • Food & beverage$54352%
  • Education$586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,044 in reported general payments places this provider in the 30th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$199,200
Medicare patients
1,319
Services billed
3,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban537$516,866
EntrestoSacubitril/Valsartan235$203,568
XareltoRivaroxaban178$179,962
JardianceEmpagliflozin93$79,846
FarxigaDapagliflozin Propanediol20$23,464
Repatha SureclickEvolocumab23$20,334
BrilintaTicagrelor27$20,155
Potassium Chloride657$10,285
Ranolazine ErRanolazine74$10,193
Diltiazem 24hr Er (Cd)Diltiazem Hcl240$7,469
Atorvastatin Calcium624$5,386
Losartan Potassium548$5,127
Bumetanide146$4,983
Metoprolol Succinate402$4,906
SotalolSotalol Hcl305$4,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$12$203,568235 claims
Johnson & JohnsonXarelto$43$179,962178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Pontiac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →